Literature DB >> 33489096

Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen-Negative Patients: An Asian Perspective.

Tung-Hung Su1,2,3, Jia-Horng Kao1,2,3,4,5.   

Abstract

Entities:  

Year:  2021        PMID： 33489096      PMCID： PMC7805293          DOI： 10.1002/cld.950

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  16 in total

Review 1.  Can we stop nucleoside analogues before HBsAg loss?

Authors:  Margarita Papatheodoridi; George Papatheodoridis
Journal:  J Viral Hepat       Date:  2019-03-27       Impact factor: 3.728

2.  JSH Guidelines for the Management of Hepatitis B Virus Infection.

Authors: 
Journal:  Hepatol Res       Date:  2014-01       Impact factor: 4.288

3.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

4.  Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.

Authors:  Tung-Hung Su; Hung-Chih Yang; Tai-Chung Tseng; Jyh-Ming Liou; Chen-Hua Liu; Chi-Ling Chen; Pei-Jer Chen; Ding-Shinn Chen; Chun-Jen Liu; Jia-Horng Kao
Journal:  J Infect Dis       Date:  2018-03-28       Impact factor: 5.226

Review 5.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

6.  Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).

Authors:  Kin Seng Liem; Scott Fung; David K Wong; Colina Yim; Seham Noureldin; Jiayun Chen; Jordan J Feld; Bettina E Hansen; Harry L A Janssen
Journal:  Gut       Date:  2019-08-28       Impact factor: 23.059

7.  Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop?

Authors:  Jia-Horng Kao; Thomas Berg
Journal:  Gut       Date:  2019-09-16       Impact factor: 23.059

8.  Taiwan consensus statement on the management of chronic hepatitis B.

Authors:  Rong-Nan Chien; Jia-Horng Kao; Cheng-Yuan Peng; Chien-Hung Chen; Chun-Jen Liu; Yi-Hsiang Huang; Tsung-Hui Hu; Hwa-I Yang; Sheng-Nan Lu; Yen-Hsuan Ni; Won-Long Chuang; Chuan-Mo Lee; Jaw-Chin Wu; Pei-Jer Chen; Yun-Fan Liaw
Journal:  J Formos Med Assoc       Date:  2018-12-06       Impact factor: 3.282

9.  Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.

Authors:  Wen-Juei Jeng; Yi-Cheng Chen; Rong-Nan Chien; I-Shyan Sheen; Yun-Fan Liaw
Journal:  Hepatology       Date:  2018-05-06       Impact factor: 17.425

10.  Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update).

Authors:  Jinlin Hou; Guiqiang Wang; Fusheng Wang; Jun Cheng; Hong Ren; Hui Zhuang; Jian Sun; Lanjuan Li; Jie Li; Qinghua Meng; Jingmin Zhao; Zhongping Duan; Jidong Jia; Hong Tang; Jifang Sheng; Jie Peng; Fengmin Lu; Qing Xie; Lai Wei
Journal:  J Clin Transl Hepatol       Date:  2017-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.